Cargando…
Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial
BACKGROUND: The interaction between thrombosis and inflammation appears central to COVID-19-associated coagulopathy and likely contributes to poor outcomes. Tissue factor is a driver of disordered coagulation and inflammatory signaling in viral infections and is important for viral replication; ther...
Autores principales: | Hess, Connie N., Capell, Warren H., Bristow, Michael R., Ruf, Wolfram, Szarek, Michael, Morrow, David A., Nicolau, Jose C., Graybill, Christopher A., Marshall, Debra, Hsia, Judith, Bonaca, Marc P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720379/ https://www.ncbi.nlm.nih.gov/pubmed/34986394 http://dx.doi.org/10.1016/j.ahj.2021.12.010 |
Ejemplares similares
-
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial
por: Hess, Connie N., et al.
Publicado: (2023) -
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
por: Capell, Warren H., et al.
Publicado: (2021) -
Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
por: Reddy, K Rajender, et al.
Publicado: (2012) -
Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial()
por: Ramacciotti, Eduardo, et al.
Publicado: (2021) -
Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom
por: Török, M Estée, et al.
Publicado: (2021)